FRAX1036 is a selective inhibitor of p21-activated kinases (PAKs), particularly targeting PAK1, PAK2, and PAK3. It is primarily utilized in medical research to study kinase signaling pathways involved in cancer, inflammatory disorders, and other diseases. Researchers employ FRAX1036 to evaluate its efficacy in inhibiting PAK activity, which plays a role in cell proliferation, migration, and survival. This inhibition has potential therapeutic implications for developing treatments against various cancers and fibrosis-related conditions. In preclinical studies, FRAX1036 aids in elucidating molecular mechanisms of disease and assessing its viability as a drug candidate. Additionally, it is used in biochemical assays to investigate kinase activity and signal transduction, offering insights into cellular processes and therapeutic intervention points.